+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Burns - Market Insight, Epidemiology and Market Forecast - 2032

  • PDF Icon

    Report

  • 227 Pages
  • July 2022
  • Region: Global
  • DelveInsight
  • ID: 5438505
UP TO OFF until Dec 31st 2022
This ‘Burns-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Burns historical and forecasted epidemiology as well as the Burns market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Burns market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Burns market size from 2022 to 2032. The Report also covers current Burns treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Burns Disease Understanding and Treatment Algorithm


Burns Overview


Burn injuries are underappreciated injuries that are associated with substantial morbidity and mortality. Burn injuries, particularly severe burns, are accompanied by an immune and inflammatory response, metabolic changes, and distributive shock that can be challenging to manage and can lead to multiple organ failures. Of great importance is that the injury affects not only physical health but also the patient's mental health and quality of life.

Burn injuries are underappreciated trauma that can affect anyone, anytime and anywhere. The injuries can be caused by friction, cold, heat, radiation, chemical, or electric sources, but most burn injuries are caused by heat from hot liquids, solids, or fire. Although all burn injuries involve tissue destruction due to energy transfer, different causes can be associated with different physiological and pathophysiological responses.

Burns Diagnosis


The determination of the severity of a burn depends on the depth of the burn and the width of the area. It is necessary to wait for 24-48 h to determine the exact burn grade, as the depth of the burn may increase due to edema and infection. The depth of the burn varies according to the type of the causative agent, the degree of temperature, and the thickness and vascularity of the affected skin area. Accurate assessment of the severity of a burn injury is paramount because it forms the basis for all subsequent treatment decisions, triage plans, and assessment of medical futility. Whenever possible, decisions about proceeding after diagnosis and screening should incorporate patient preferences and expectations about the quality of life. Optimal assessment of the severity of burn injury must involve a systematic, methodical approach, such as that described in course materials for the Advanced Trauma Life Support (ATLS) by the American College of Surgeons Committee on Trauma, Emergency Management of the Severe Burn (EMSB) by the Australian and New Zealand Burn Association, and Advanced Burn Life Support (ABLS) by the ABA.

Burns Treatment
The current treatment for skin burn involves medications, wound dressings, therapy, and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.

Medical treatment includes water-based treatments (Ultrasound mist therapy to clean and stimulate the wound tissue), fluids to prevent dehydration (intravenous (IV) fluids to prevent dehydration and organ failure), pain and anxiety medications (morphine and anti-anxiety medications), creams and ointments (bacitracin and silver sulfadiazine), dressings (wound dressings), and common topical antimicrobials such as silver sulfadiazine (SSD), cerium plus SSD, silver nitrate, mafenide, bacitracin, and Xeroform. Apart from the above-mentioned pharmacological treatment options, the most important management practice involves surgery. Early autografting then build on these improvements by rapidly closing excised wounds, further reducing infection risk, decreasing pain, and enabling earlier mobilization. If there are concerns about the viability or bacterial load on the wound bed and/or the patient's stability, allografting is preferred to cover the debrided wound temporarily. Some commercially available skin substitutes are Epicel, StrataGraft, RECELL System, Split thickness skin graft, Kerecis Omega3 products, and several others.

Burns Epidemiology


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Burn Patients Requiring Treatment, Gender-specific Incident Cases of Treated Burn Injuries, Etiology-specific Incident Cases of Treated Burn Injuries, Severity-specific Incident Cases of Treated Burn Injuries, and Incident Cases of Hospitalized Burn Patients scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

  • In 2021, total incident population of burn injuries that required medical treatment in seven major markets were reported to be 1,864,208.
  • The number of hospitalized burn cases in the seven major market is expected to increase at an effective CAGR during the study period, i.e. 2019-2032.
  • The estimates suggest the United States had highest incident population of burn injuries that required medical treatment with 661,900 cases in 2021.
  • According to our analysis, after fire/flame (41%), scald was the foremost contributing cause for burn injuries in the US, occupying 31.4% of total incident cases of treatment taking burn injuries.
  • Our analysis indicates that the majority of burn injury cases taking treatment are males. This is accompanied by the fact that major burn injuries occur at workplaces; thus, the burn injury cases in males are predominantly higher. There were 410,378 male and 251,522 female cases of treated burn injuries in 2021, in the US.
  • In 2021, the severity-specific incident cases were 144,294; 386,550; 19,857; and 111,199 for first-degree, second-degree, third-degree, and unspecified, respectively in the United States.
  • According to our assessments for the United States, the estimated cases of hospitalized burn patients in 2021 were 76,383.
  • Among the EU5 countries, the UK had the highest incident population of burn patients that require medical treatment with 275,829 cases, followed by France (203,690 cases) and Spain (143,209 cases) in 2021. On the other hand, Italy had the lowest incident population (122,890).
  • Japan had 328,255 incident cases of burn injuries requiring medical treatment in 2021, the second-highest of all other countries in 7MM after the US.

Burns Epidemiology


The epidemiology segment also provides the Burns epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Burns Drug Chapters


Burns Marketed Drug
NexoBrid/KMW-1: MediWound Germany GmbH/Kaken Pharmaceutical Co., Ltd.

NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, is an easy-to-use, topically-applied product that removes eschar in 4 h without harming the surrounding healthy tissues. NexoBrid's rapid and selective debridement alleviates the known risks associated with eschars, such as infection, eventual sepsis, wound deterioration, and consequential scarring. It allows physicians to reach an informed decision on further treatment at an earlier stage by direct visual assessment of the actual burn depth. Furthermore, it minimizes the burden associated with invasive surgical procedures, reduces the need for skin grafting and sacrifice of healthy tissue from donor sites on a patient's body, and generally results in a more favorable overall long-term patient outcome. NexoBrid has been investigated in hundreds of patients across more than 22 countries and four continents in nine completed Phase II, Phase III, and postmarketing clinical studies. In clinical trials, the product has been referred to as “Debridase” and “Debrase.”

Kerecis Omega3: Kerecis
Kerecis (formally known as Marigen) produces skin and tissue-based products for use in surgery and for treating wounds. Kerecis Omega3 is intact fish skin rich in naturally occurring Omega3 polyunsaturated fatty acids. When grafted onto damaged human tissue such as a burn or a diabetic wound, the material recruits the body's own cells and is ultimately converted into living tissue. Kerecis has a wide range of products for the treatment of burns that includes Kerecis Omega3 Wound, Kerecis Omega3 OR, Kerecis Omega3 MicroGraft, Kerecis Omega3 GraftGuide, and Kerecis Primary Wound Spray, some of which are approved and some are not. Kerecis products utilize multiple patented fatty-acid technologies to protect and regenerate tissue across two core technologies: Kerecis Omega3 Fish Skin and Kerecis Omega3 Viruxide.

StrataGraft: Mallinckrodt Pharmaceuticals
StrataGraft is a viable, bioengineered, allogeneic, cellularized scaffold product derived from keratinocytes grown on gelled collagen-containing dermal fibroblasts. It is designed to deliver viable cells to support the body's own ability to heal and contains metabolically active cells that produce and secrete a variety of growth factors and cytokines. Growth factors and cytokines are known to be involved in wound repair and regeneration. The product is designed with both dermal and epidermal layers composed of well-characterized human cells. StrataGraft is intended to be applied in appropriate aseptic conditions, such as the operating room, and can be sutured, stapled, or secured with a tissue adhesive. In June 2021, Mallinckrodt Pharmaceuticals announced that the US FDA had approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).

List to be continued in the report…

Burns Emerging Drugs


MW-III: Skingenix
MW-III, a product by Skingenix, is a topical product being evaluated for second-degree burns in adult patients. The drug is a botanical drug product developed for treating burns and other cutaneous wounds, which will be made from natural ingredients such as Sesame Oil, Coptidis Rhizoma, Scutellariae Radix, Phellodendri Chinesis Cortex, and Pheretima, and formulated as an ointment with Beeswax. Skingenix, Inc. is currently pursuing several indications under an Investigational New Drug Application (IND) for their investigational product (MW-III) in the US. The company has recently initiated a Phase II clinical study to assess the safety and efficacy of their investigational product in patients with burn injuries in the US.

EHSG-KF (denovoSkin): CUTISS AG
denovoSkin being developed by CUTISS AG and others, is bio-engineered within large quantities (>1:100) with a thick, double layer, robust structure. denovoSkin is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). denovoSkin has successfully completed Phase I in pediatric patients. Phase II clinical trials are now underway in Europe and Switzerland and are expected to be completed by 2022. The company is also working on the scale-up of the production process by means of automation. It is currently tested in three European multi-centric Phase II efficacy clinical studies (NCT03227146, NCT03229564, NCT03394612).

List to be continued in the report…

Burns Market Outlook


In the current market scenario, the standard treatment for skin burn involves medications, wound dressings, therapy, and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.

Apart from the pharmacological treatment options, the most important management practice involves surgery. Early autografting then build on these improvements by rapidly closing excised wounds, further reducing infection risk, decreasing pain, and enabling earlier mobilization. If there are concerns about the viability or bacterial load on the wound bed and/or the patient's stability, allografting is preferred to cover the debrided wound temporarily.

The surgical approach is to leave no full-thickness burned tissue behind and debride down to viable tissue. The gold-standard burn coverage is autologous split-thickness skin grafts (STSGs). Skin substitutes have developed over the past decade from temporary materials used to induce wound healing to permanent tissue-engineered materials that offer definitive healing.

The common principle of skin substitutes is to deliver proteins, growth factors and/or cells via a delivery vehicle or matrix that will then be integrated into the wound and form new autologous skin. Common skin substitutes include cadaver skin (allograft) and porcine skin (xenograft), which provide temporary coverage for up to 14 days before inevitable rejection. To overcome the need for uninjured donor skin in autologous STSG, artificial skin substitutes have been introduced to the market and include TransCyte, CEA, cultured skin substitutes, and various others.

Some commercially available skin substitutes are Epicel, StrataGraft, RECELL System, Split thickness skin graft, Kerecis Omega3 products, and several others.

The dynamics of the skin burn market are anticipated to change in the coming years due to the improvement in the treatment, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. Companies like CUTISS AG, RenovaCare, Mallinckrodt Pharmaceuticals, and others across the globe are working toward developing more advanced treatment therapies for skin burns.

Key Findings

  • The market size for Burns injury was USD 827 million in 2021 in the United States.
  • The publisher's analysts estimate that the market is expected to show positive growth, mainly attributed to the increase in population, increasing incidence of burn injury and also, the launch of upcoming therapies during the forecast period. Through this, the market size is set to show an extensive jump by end of 2032, at a CAGR of 1.99% during the study period (2019-2032) in the 7MM.
  • The Burns market size in the EU5 was USD 491 million in 2021. EU5 accounted for nearly 32% of the total 7MM market size. Among the EU5 countries, the United Kingdom holds the highest market size of USD 160 million followed by France (USD 103 million) and Germany (USD 85 million). Spain holds the least market size of USD 71 million among the EU5 countries in 2021.
  • The Burns market size in Japan was USD 222 million in 2021. Japan accounted for 14% of the total 7MM market size.

The United States Market Outlook


This section provides the total Burns market size and; market size by therapies in the United States.

EU-5 Market Outlook


The total Burns market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook


The total Burns market size and market size by therapies in Japan are provided.

Burns Drugs Uptake


This section focuses on the rate of uptake of the potential drugs recently launched in the Burns market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Burns market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Burns Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Burns emerging therapies.

Reimbursement Scenario in Burns


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis


The publisher performs competitive market Intelligence analysis of the Burns market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Burns, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Burns epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Burns is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Burns market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Burns market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the Burns market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Burns R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Burns. The launch of emerging therapies will significantly impact the Burns market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Burns Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Burns Pipeline Analysis
  • Burns Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Burns Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Burns Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Burns Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions


Market Insights:

  • What was the Burns market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Burns total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Burns market size during the forecast period (2022-2032)?
  • At what CAGR, the Burns market is expected to grow at the 7MM level during the forecast period (2022-2032)?
  • What would be the Burns market outlook across the 7MM during the forecast period (2022-2032)?
  • What would be the Burns market growth till 2032 and what will be the resultant market size by the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Burns?
  • What is the historical Burns patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Burns at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Burns?
  • Out of the above-mentioned countries, which country would have the highest population of Burns during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Burns along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Burns in the US and Europe?
  • What are the Burns marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Burns?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Burns?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Burns therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Burns and their status?
  • What are the key designations that have been granted for the emerging therapies for Burns?
  • What are the 7MM historical and forecasted market of Burns?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving Burns.
  • To understand the future market competition in the Burns market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Burns in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Burns market.
  • To understand the future market competition in the Burns market.

Table of Contents

1. Key Insights2. Report Introduction
3. Burns Market Overview at a Glance
3.1. Market Share (%) Distribution of Burns by Therapies/Procedures in 2019
3.2. Market Share (%) Distribution of Burns by Therapies/Procedures in 2032
4. Burn Market: Future Prospective5. Executive Summary of Burns6. Key Events
7. Burns: Disease Background and Overview
7.1. Introduction
7.2. Etiology
7.3. Classification of Burns
7.4. Evaluation of Burn Severity
7.5. Pathophysiology
7.6. Phases of Wound Healing
7.7. Systemic Response
7.8. Diagnosis, screening, and prevention
7.8.1. Diagnosis Guidelines
7.8.1.1. The wound/burn guidelines - 6: Guidelines for the management of burns
7.9. Management and Treatment
7.9.1. Diagnostic and Treatment Algorithm
7.9.2. Treatment Guidelines
7.9.2.1. American Burn Association Guidelines on the Management of Acute Pain in the Adult Burn Patient
7.9.2.2. European Practice Guidelines for Burn Care
7.9.2.3. The wound/burn guidelines - 6: Guidelines for the management of burns
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
8.3.1. The US: Assumptions and Rationale
8.3.2. EU5: Assumptions and Rationale
8.3.3. Japan: Assumptions and Rationale
8.4. Incident Cases of Burn Patients Requiring Treatment in the 7MM
8.5. Incident Cases of Hospitalized Burn Patients in the 7MM
8.6. The United States
8.6.1. Incident Cases of Burn Patients Requiring Treatment in the US
8.6.2. Gender-specific Incident Cases of Treated Burn Injuries in the US
8.6.3. Etiology-specific Incident Cases of Treated Burn Injuries in the US
8.6.4. Severity-specific Incident Cases of Treated Burn Injuries in the US
8.6.5. Incident Cases of Hospitalized Burn Patients in the US
8.7. EU-5
8.7.1. Germany
8.7.1.1. Incident Cases of Burn Patients Requiring Treatment
8.7.1.2. Gender-specific Incident Cases of Treated Burn Injuries
8.7.1.3. Etiology-specific Incident Cases of Treated Burn Injuries
8.7.1.4. Severity-specific Incident Cases of Treated Burn Injuries
8.7.1.5. Incident Cases of Hospitalized Burn Patients
8.7.2. France
8.7.2.1. Incident Cases of Burn Patients Requiring Treatment
8.7.2.2. Gender-specific Incident Cases of Treated Burn Injuries
8.7.2.3. Etiology-specific Incident Cases of Treated Burn Injuries
8.7.2.4. Severity-specific Incident Cases of Treated Burn Injuries
8.7.2.5. Incident Cases of Hospitalized Burn Patients
8.7.3. Italy
8.7.3.1. Incident Cases of Burn Patients Requiring Treatment
8.7.3.2. Gender-specific Incident Cases of Treated Burn Injuries
8.7.3.3. Etiology-specific Incident Cases of Treated Burn Injuries
8.7.3.4. Severity-specific Incident Cases of Treated Burn Injuries
8.7.3.5. Incident Cases of Hospitalized Burn Patients
8.7.4. Spain
8.7.4.1. Incident Cases of Burn Patients Requiring Treatment
8.7.4.2. Gender-specific Incident Cases of Treated Burn Injuries
8.7.4.3. Etiology-specific Incident Cases of Treated Burn Injuries
8.7.4.4. Severity-specific Incident Cases of Treated Burn Injuries
8.7.4.5. Incident Cases of Hospitalized Burn Patients
8.7.5. The UK
8.7.5.1. Incident Cases of Burn Patients Requiring Treatment
8.7.5.2. Gender-specific Incident Cases of Treated Burn Injuries
8.7.5.3. Etiology-specific Incident Cases of Treated Burn Injuries
8.7.5.4. Severity-specific Incident Cases of Treated Burn Injuries
8.7.5.5. Incident Cases of Hospitalized Burn Patients
8.8. Japan
8.8.1. Incident Cases of Burn Patients Requiring Treatment in Japan
8.8.2. Gender-specific Incident Cases of Treated Burn Injuries in Japan
8.8.3. Etiology-specific Incident Cases of Treated Burn Injuries in Japan
8.8.4. Severity-specific Incident Cases of Treated Burn Injuries in Japan
8.8.5. Incident Cases of Hospitalized Burn Patients in Japan
9. Patient Journey
10. Marketed Therapies
10.1. Marketed Products for Burn
10.2. NexoBrid/KMW-1: MediWound Germany GmbH/Kaken Pharmaceutical Co., Ltd.
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental activities
10.2.4. Clinical Development
10.2.5. Clinical Trials Information
10.2.6. Safety and Efficacy
10.2.7. Product Profile
10.3. Kerecis Omega3: Kerecis
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental activities
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Product Profile
10.4. StrataGraft: Mallinckrodt Pharmaceuticals
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Other Developmental activities
10.4.4. Clinical Development
10.4.5. Clinical Trials Information
10.4.6. Safety and Efficacy
10.4.7. Product Profile
10.5. RECELL System: Avita Medical
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Other Developmental activities
10.5.4. Clinical Development
10.5.5. Clinical Trials Information
10.5.6. Safety and Efficacy
10.5.7. Product Profile
10.6. Epicel: Vericel Corporation
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Safety and Efficacy
10.6.4. Product Profile
10.7. KeraStat Gel: KeraNetics
10.7.1. Product Description
10.7.2. Regulatory Milestones
10.7.3. Other Developmental activities
10.7.4. Clinical Development
10.7.5. Clinical Trials Information
10.7.6. Product Profile
10.8. Integra Meshed Dermal Regeneration Template: Integra LifeSciences Corporation
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Safety and Efficacy
10.8.4. Product Profile
10.9. NovoSorb BTM: PolyNovo
10.9.1. Product Description
10.9.2. Regulatory Milestones
10.9.3. Other Developmental activities
10.9.4. Clinical Development
10.9.5. Clinical Trials Information
10.9.6. Safety and Efficacy
10.9.7. Product Profile
10.10. Hyalomatrix (Esterified Hyaluronic Acid Matrix): Medline Industries/Anika Therapeutics, Inc.
10.10.1. Product Description
10.10.2. Regulatory Milestones
10.10.3. Other Developmental activities
10.10.4. Product Profile
10.11. Cytal Burn Matrix Devices: ACell, Inc. / Integra LifeSciences
10.11.1. Product Description
10.11.2. Regulatory Milestones
10.11.3. Other Developmental activities
10.11.4. Product Profile
10.12. Filsuvez, Oleogel-S10 (Episalvan): Amryt Pharma
10.12.1. Product Description
10.12.2. Regulatory Milestones
10.12.3. Other Developmental activities
10.12.4. Clinical Development
10.12.5. Clinical Trials Information
10.12.6. Safety and Efficacy
10.12.7. Product Profile
11. Emerging Drugs
11.1. Key Cross Competition
11.2. DenovoSkin (EHSG-KF): CUTISS AG
11.2.1. Product Description
11.2.2. Other Developmental activity
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.2.7. Analysts’ Views
11.3. MW-III: Skingenix
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Product Profile
11.3.6. Analysts’ Views
11.4. CellMist System: RenovaCare
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Product Profile
12. Burns: Seven Major Market Analysis
12.1. Key Findings
12.2. Methodology of Burns Market
12.3. Market Size of Burn in the 7MM
12.4. Market Size of Burn by Therapies/Procedures in the 7MM
12.5. Key Market Forecast Assumptions
12.6. Potential of Current and Emerging Therapies
12.7. Market Outlook
12.8. Market Size of Burn in the United States
12.8.1. Total Market Size of Burn
12.8.2. Market Size of Burn by Therapies/Procedures
12.9. Market Size of Burn in EU-5
12.9.1. Total Market Size of Burn
12.9.2. Market Size of Burn by Therapies/Procedures
12.10. Market Size of Burn in Japan
12.10.1. Total Market Size of Burn
12.10.2. Market Size of Burn by Therapies/Procedures
13. Key Opinion Leaders’ Views14. Market Drivers15. Market Barriers16. SWOT Analysis17. Unmet Needs18. Reimbursement and Market Access
19. Appendix
19.1. Bibliography
19.2. Abbreviations
19.3. Report Methodology
20. Publisher Capabilities21. Disclaimer22. About the Publisher
List of Tables
Table 1: Summary of Burns Market and Epidemiology (2019-2032)
Table 2: Key Events
Table 3: The Haddon Matrix for burn prevention
Table 4: Recommendations
Table 5: Incident Cases of Burn Patients Requiring Treatment in the 7MM, in ‘000’ (2019-2032)
Table 6: Incident Cases of Hospitalized Burn Patients in the 7MM, in ‘000’ (2019-2032)
Table 7: Incident Cases of Burn Patients Requiring Treatment in the US (2019-2032)
Table 8: Gender-specific Incident Cases of Treated Burn Injuries in the US (2019-2032)
Table 9: Etiology-specific Incident cases of Cases of Treated Burn Injuries in the US (2019-2032)
Table 10: Severity-specific Incident cases of Treated Burn Injuries in the US (2019-2032)
Table 11: Incident Cases of Hospitalized Burn Patients in the US (2019-2032)
Table 12: Incident Cases of Burn Patients Requiring Treatment in EU-5 (2019-2032)
Table 13: Gender-specific Incident Cases of Treated Burn Injuries in Germany(2019-2032)
Table 14: Gender-specific Incident Cases of Treated Burn Injuries in France (2019-2032)
Table 15: Gender-specific Incident Cases of Treated Burn Injuries in Italy (2019-2032)
Table 16: Gender-specific Incident Cases of Treated Burn Injuries in Spain (2019-2032)
Table 17: Gender-specific Incident Cases of Treated Burn Injuries in the UK (2019-2032)
Table 18: Gender-specific Incident Cases of Treated Burn Injuries in the EU-5 (2019-2032)
Table 19: Etiology-specific Incident cases of Cases of Treated Burn Injuries in Germany (2019-2032)
Table 20: Etiology-specific Incident cases of Cases of Treated Burn Injuries in France (2019-2032)
Table 21: Etiology-specific Incident cases of Cases of Treated Burn Injuries in Italy (2019-2032)
Table 22: Etiology-specific Incident cases of Cases of Treated Burn Injuries in Spain (2019-2032)
Table 23: Etiology-specific Incident cases of Cases of Treated Burn Injuries in the UK (2019-2032)
Table 24: Etiology-specific Incident cases of Cases of Treated Burn Injuries in the EU-5 (2019-2032)
Table 25: Severity-specific Incident cases of Treated Burn Injuries in Germany (2019-2032)
Table 26: Severity-specific Incident cases of Treated Burn Injuries in France (2019-2032)
Table 27: Severity-specific Incident cases of Treated Burn Injuries in Italy (2019-2032)
Table 28: Severity-specific Incident cases of Treated Burn Injuries in Spain (2019-2032)
Table 29: Severity-specific Incident cases of Treated Burn Injuries in the UK (2019-2032)
Table 30: Severity-specific Incident cases of Treated Burn Injuries in the EU-5 (2019-2032)
Table 31: Incident Cases of Hospitalized Burn Patients in EU-5 (2019-2032)
Table 32: Incident Cases of Burn Patients Requiring Treatment in Japan (2019-2032)
Table 33: Gender-specific Incident Cases of Treated Burn Injuries in Japan (2019-2032)
Table 34: Etiology-specific Incident Cases of Treated Burn Injuries in Japan (2019-2032)
Table 35: Severity-specific Incident Cases of Treated Burn Injuries in Japan (2019-2032)
Table 36: Incident Cases of Hospitalized Burn Patients in Japan (2019-2032)
Table 37: Hemostatic adjuncts FDA approved for hemostasis
Table 38: FDA approved therapies for the management of infection
Table 39: Human cells, tissues, and Cellular and Tissue-based Products approved for burns
Table 40: FDA cleared and approved epidermal, dermal, and complete substitutes for burn wounds
Table 41: FDA-approved therapies for scar mitigation
Table 42: NexoBrid, Clinical Trial Description, 2022
Table 43: Kerecis Omega3 Burn, Clinical Trial Description, 2022
Table 44: StrataGraft, Clinical Trial Description, 2022
Table 45: RECELL Autologous Cell Harvesting Device, Clinical Trial Description, 2022
Table 46: KeraStat Gel, Clinical Trial Description, 2022
Table 47: NovoSorb Biodegradable Temporising Matrix (BTM), Clinical Trial Description, 2022
Table 48: Oleogel-S10 ointment, Clinical Trial Description, 2022
Table 49: Comparison of emerging drugs under development, 2022
Table 50: EHSG-KF (synonym denovoSkin), Clinical Trial Description, 2022
Table 51: MW-III, Clinical Trial Description, 2022
Table 52: CellMist System, Clinical Trial Description, 2022
Table 53: Market Size of Burn in the 7MM in USD Million (2019-2032)
Table 54: Market Size of Burn by Therapies/Procedures in the 7MM in USD Million (2019-2032)
Table 55: Key Market Forecast Assumptions for EHSG-KF (denovoSkin)
Table 56: Key Market Forecast Assumptions for NexoBrid (KMW-1)
Table 57: Key Market Forecast Assumptions for StrataGraft
Table 58: United States Market Size of Burn in USD Million (2019-2032)
Table 59: Market Size of Burn by Therapies/Procedures in the US in USD Million (2019-2032)
Table 60: EU-5 Market Size of Burn in USD Million (2019-2032)
Table 61: Market Size of Burn by Therapies/Procedures in Germany in USD Million (2019-2032)
Table 62: Market Size of Burn by Therapies/Procedures in France in USD Million (2019-2032)
Table 63: Market Size of Burn by Therapies/Procedures in Italy in USD Million (2019-2032)
Table 64: Market Size of Burn by Therapies/Procedures in Spain in USD Million (2019-2032)
Table 65: Market Size of Burn by Therapies/Procedures in the UK in USD Million (2019-2032)
Table 66: Market Size of Burn by Therapies/Procedures in the EU-5 in USD Million (2019-2032)
Table 67: Market Size of Burn in Japan, in USD Million (2019-2032)
Table 68: Market Size of Burn by Therapies/Procedures in Japan in USD Million (2019-2032)
Table 69: Reimbursement Guide CPT Codes for the Application of Cell Suspension Autografts Recommended by the American Burn Association
Table 70: Common MS-DRGs for Patients Admitted for Burn Treatment With RECELL System
Table 71: Coding Information for Integra Meshed Dermal Regeneration Template
Table 72: Reimbursement Codes Associated With Epicel and the CEA Procedure in Burn Treatment
Table 73: Abbreviations Used in Report
List of Figures
Figure 1: The Five Mechanisms That Can Cause a Burn
Figure 2: Burn Depth
Figure 3: Wallace Rule of Nines
Figure 4: Lund and Browder Chart
Figure 5: Jackson’s Burns Zones
Figure 6: Systemic Changes That Occur After a Burn Injury
Figure 7: Four Phases of Wound Healing
Figure 8: CEA, cultured epithelial autograft
Figure 9: The phases of burn care
Figure 10: Diagnostic and therapeutic algorithms for burn injury
Figure 11: Incident Cases of Burn Patients Requiring Treatment in the 7MM (2019-2032)
Figure 12: Incident Cases of Hospitalized Burn Patients in the 7MM (2019-2032)
Figure 13: Incident Cases of Burn Patients Requiring Treatment in the US (2019-2032)
Figure 14: Gender-specific Incident Cases of Treated Burn Injuries in the US (2019-2032)
Figure 15: Etiology-specific Incident Cases of Treated Burn Injuries in the US (2019-2032)
Figure 16: Severity-specific Incident cases of Treated Burn Injuries in the US (2019-2032)
Figure 17: Incident Cases of Hospitalized Burn Patients in the US (2019-2032)
Figure 18: Incident Cases of Burn Patients Requiring Treatment in Germany (2019-2032)
Figure 19: Gender-specific Incident Cases of Treated Burn Injuries in Germany (2019-2032)
Figure 20: Etiology-specific Incident Cases of Treated Burn Injuries in Germany (2019-2032)
Figure 21: Severity-specific Incident Cases of Treated Burn Injuries in Germany (2019-2032)
Figure 22: Incident Cases of Hospitalized Burn Patients in Germany (2019-2032)
Figure 23: Incident Cases of Burn Patients Requiring Treatment in France (2019-2032)
Figure 24: Gender-specific Incident Cases of Treated Burn Injuries in France (2019-2032)
Figure 25: Etiology-specific Incident Cases of Treated Burn Injuries in France (2019-2032)
Figure 26: Severity-specific Incident Cases of Treated Burn Injuries in France (2019-2032)
Figure 27: Incident Cases of Hospitalized Burn Patients in France (2019-2032)
Figure 28: Incident Cases of Burn Patients Requiring Treatment in Italy (2019-2032)
Figure 29: Gender-specific Incident Cases of Treated Burn Injuries in Italy (2019-2032)
Figure 30: Etiology-specific Incident Cases of Treated Burn Injuries in Italy (2019-2032)
Figure 31: Severity-specific Incident Cases of Treated Burn Injuries in Italy (2019-2032)
Figure 32: Incident Cases of Hospitalized Burn Patients in Italy (2019-2032)
Figure 33: Incident Cases of Burn Patients Requiring Treatment in Spain (2019-2032)
Figure 34: Gender-specific Incident Cases of Treated Burn Injuries in Spain (2019-2032)
Figure 35: Etiology-specific Incident Cases of Treated Burn Injuries in Spain (2019-2032)
Figure 36: Severity-specific Incident Cases of Treated Burn Injuries in Spain (2019-2032)
Figure 37: Incident Cases of Hospitalized Burn Patients in Spain (2019-2032)
Figure 38: Incident Cases of Burn Patients Requiring Treatment in the UK (2019-2032)
Figure 39: Gender-specific Incident Cases of Treated Burn Injuries in the UK (2019-2032)
Figure 40: Etiology-specific Incident Cases of Treated Burn Injuries in the UK (2019-2032)
Figure 41: Severity-specific Incident Cases of Treated Burn Injuries in the UK (2019-2032)
Figure 42: Incident Cases of Hospitalized Burn Patients in the UK (2019-2032)
Figure 43: Incident Cases of Burn Patients Requiring Treatment in Japan (2019-2032)
Figure 44: Gender-specific Incident Cases of Treated Burn Injuries in Japan (2019-2032)
Figure 45: Etiology-specific Incident Cases of Treated Burn Injuries in Japan (2019-2032)
Figure 46: Severity-specific Incident Cases of Treated Burn Injuries in Japan (2019-2032)
Figure 47: Incident Cases of Hospitalized Burn Patients in Japan (2019-2032)
Figure 48: Patient Journey
Figure 49: Market Size of Burn in the 7MM in USD Million (2019-2032)
Figure 50: Market Size of Burn by Therapies/Procedures in the 7MM in USD Million (2019-2032)
Figure 51: Market Size of Burn in the United States, USD Millions (2019-2032)
Figure 52: Market Size of Burn by Therapies/Procedures in the United States, in USD Million (2019-2032)
Figure 53: Market Size of Burn in EU5, USD Millions (2019-2032)
Figure 54: Market Size of Burn by Therapies/Procedures, in the EU5, in USD Million (2019-2032)
Figure 55: Market Size of Burn in Japan, USD Millions (2019-2032)
Figure 56: Market Size of Burn by Therapies/Procedures in Japan, in USD Million (2019-2032)
Figure 57: Market Drivers
Figure 58: Market Barriers
Figure 59: SWOT Analysis
Figure 60: Unmet Needs

Companies Mentioned

A selection of companies mentioned in this report includes:

  • MediWound Germany GmbH
  • Kaken Pharmaceutical Co., Ltd.
  • Kerecis
  • Mallinckrodt Pharmaceuticals
  • Avita Medical
  • Vericel Corporation
  • KeraNetics
  • Integra LifeSciences Corporation
  • PolyNovo
  • Medline Industries
  • Anika Therapeutics, Inc.
  • ACell, Inc.
  • Amryt Pharma
  • CUTISS AG
  • Skingenix
  • RenovaCare